Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May;31(5):865-870.
doi: 10.1007/s00192-019-04186-3. Epub 2019 Dec 18.

Posterior tibial nerve stimulation for overactive bladder-techniques and efficacy

Alka A Bhide  1 , Visha Tailor  2 , Ruwan Fernando  2 , Vik Khullar  2 , Giuseppe Alessandro Digesu  2
Affiliations

Posterior tibial nerve stimulation for overactive bladder-techniques and efficacy

Alka A Bhide et al. Int Urogynecol J. 2020 May.

Abstract

The ideal treatment for overactive bladder is still elusive. In those where medication fails to improve symptoms options include invasive treatments such as botulinum toxin-A, sacral neural stimulation or posterior tibial nerve stimulation. Scientific professional society guidelines advise percutaneous posterior tibial nerve stimulation as a third line treatment option only after multi-disciplinary team review as well as failure of both conservative and pharmacological management. The aim of this article is to review all techniques for tibial nerve stimulation and their efficacy.

Keywords: Implantable; Neuromodulation; Overactive bladder; Percutaneous; Tibial nerve stimulation; Transcutaneous.

PubMed Disclaimer

Conflict of interest statement

None.

References

    1. Bo K, Frawley HC, Haylen BT, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for the conservative and nonpharmacological management of female pelvic floor dysfunction. Int Urogynecol J. 2017;28(2):191–213. doi: 10.1007/s00192-016-3123-4. - DOI - PubMed
    1. Rachaneni S, Latthe P. Effectiveness of BTX-A and neuromodulation in treating OAB with or without detrusor overactivity: a systematic review. Int Urogynecol J. 2017;28(6):805–816. doi: 10.1007/s00192-016-3225-z. - DOI - PubMed
    1. Elmer-Lyon CG, Streit JA, Takacs EB, Ten Eyck PP, Bradley CS. Urinary tract infection and drug-resistant urinary tract infection after intradetrusor onabotulinumtoxinA injection versus sacral neuromodulation. Int Urogynecol J. 2019. 10.1007/s00192-019-04007-7. - PMC - PubMed
    1. Tran AM, Sand PK, Seitz MJ, Gafni-Kane A, Zhou Y, Botros SM. Does physician specialty affect persistence to pharmacotherapy among patients with overactive bladder syndrome? Int Urogynecol J. 2017;28(3):409–415. doi: 10.1007/s00192-016-3118-1. - DOI - PubMed
    1. Foust-Wright C, Wissig S, Stowell C, Olson E, Anderson A, Anger J, Cardozo L, Cotterill N, Gormley EA, Toozs-Hobson P, Heesakkers J, Herbison P, Moore K, McKinney J, Morse A, Pulliam S, Szonyi G, Wagg A, Milsom I. Development of a core set of outcome measures for OAB treatment. Int Urogynecol J. 2017;28(12):1785–1793. doi: 10.1007/s00192-017-3481-6. - DOI - PMC - PubMed

MeSH terms

Substances